Qifeng Dou
Overview
Explore the profile of Qifeng Dou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
16
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu Y, Zhang Z, Hu H, He X, Xu P, Qifeng Dou , et al.
Sci Rep
. 2024 Jun;
14(1):13883.
PMID: 38880809
The purpose of this study was to investigate the prevalence and relevant factors of nocturia and its impact on sleep quality in university students in Mainland China. A large-scale survey...
2.
Zhou B, Wang Z, Qifeng Dou , Li W, Li Y, Yan Z, et al.
J Transl Int Med
. 2023 Oct;
11(3):234-245.
PMID: 37818156
Background And Objectives: An increased risk of cardiovascular and metabolic diseases (CVMDs) among patients with cancer suggests a potential link between CVMD and cancer. The impact of CVMD on the...
3.
Li Y, Wang Y, Fan M, Li W, Meng X, Zhou H, et al.
Environ Sci Pollut Res Int
. 2023 Jul;
30(41):93697-93707.
PMID: 37515621
Urolithiasis accounts for the highest incidence of all urologic-associated hospitalizations. However, few studies have explored the effect of nitrogen dioxide (NO) on hospitalizations for urolithiasis. We included 5956 patients with...
4.
Gu C, Wang Z, Lin T, Liu Z, Han W, Zhang X, et al.
Chin Med J (Engl)
. 2023 Apr;
136(10):1207-1215.
PMID: 37010251
Background: LY01005 (Goserelin acetate sustained-release microsphere injection) is a modified gonadotropin-releasing hormone (GnRH) agonist injected monthly. This phase III trial study aimed to evaluated the efficacy and safety of LY01005...
5.
Chu J, Shi Z, Jiao Y, Han Z, Qifeng Dou , Ye J, et al.
Anticancer Drugs
. 2018 Jul;
29(9):839-846.
PMID: 29985192
Testicular cancer (TC) is the most common malignancy in men. Although the 5-year survival rate of TC patients exceeds 95%, the prognosis of patients with platinum-resistant tumors remains poor because...